57 related articles for article (PubMed ID: 38445658)
1. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
[TBL] [Abstract][Full Text] [Related]
2. Surgical outcome and risk scoring to predict survival after hepatic resection for hepatocellular carcinoma with portal vein tumor thrombosis.
Kim TS; Yang K; Choi GH; Yang HY; Kim DS; Jo HS; Choi GS; Kim KW; Yoon YC; Han J; Kim DJ; Hwang S; Kang KJ
Ann Hepatobiliary Pancreat Surg; 2024 May; 28(2):134-143. PubMed ID: 38720612
[TBL] [Abstract][Full Text] [Related]
3. Financial burden in a US cohort of patients with HCC.
Desai R; Jiang Y; VanWagner LB; Singal AG; Lieber SR
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38829203
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
[TBL] [Abstract][Full Text] [Related]
5. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.
Tao ZW; Cheng BQ; Zhou T; Gao YJ
Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):134-144. PubMed ID: 34955380
[TBL] [Abstract][Full Text] [Related]
6. Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level.
Hwang H; Kim JH; Ko E; Kim JY; Ko HK; Gwon DI; Shin JH; Kim GH; Chu HH
Br J Radiol; 2024 May; 97(1157):1038-1043. PubMed ID: 38445658
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.
Li L; Cheng N; Huang X; Weng X; Jiao Y; Liu J; Guo W
World J Surg Oncol; 2022 Feb; 20(1):30. PubMed ID: 35109883
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
11. Hepatocellular carcinoma with macrovascular invasion: need a personalized medicine for this complicated event.
Hwang H; Shim JH; Kim JH
Hepatobiliary Surg Nutr; 2024 Feb; 13(1):188-190. PubMed ID: 38322215
[No Abstract] [Full Text] [Related]
12. Intermediate-stage (BCLC stage B) infiltrative hepatocellular carcinoma: safety and efficacy of chemoembolization.
Kim SH; Kim JH; Kim GH; Kim JH; Ko HK; Chu HH; Shin JH; Gwon DI; Ko GY; Yoon HK; Aljerdah S; Kim N
Eur Radiol; 2023 Dec; 33(12):8736-8744. PubMed ID: 37466704
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.
Cho Y; Choi JW; Kwon H; Kim KY; Lee BC; Chu HH; Lee DH; Lee HA; Kim GM; Oh JS; Hyun D; Lee IJ; Rhim H;
Korean J Radiol; 2023 Jul; 24(7):606-625. PubMed ID: 37404104
[TBL] [Abstract][Full Text] [Related]
14. Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria.
Saito N; Nishiofuku H; Sato T; Maeda S; Minamiguchi K; Taiji R; Matsumoto T; Chanoki Y; Tachiiri T; Kunichika H; Marugami N; Tanaka T
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174075
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
